SQSTM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Figure 3 showed that talazoparib obviously increased the level of LC3-II and reduced the level of SQSTM1 in CML cells in a concentration-dependent manner after talazoparib treatment.